Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation

Hepatology

Volumn 52, Issue 3, 2010, Pages 1171-1172

  Rowe, Ian A ^a  

^a University of Birmingham   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; DISEASE COURSE; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PRIORITY JOURNAL; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; TREATMENT OUTCOME; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77956628287     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23702     Document Type: Letter

References (7)

1. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. HEPATOLOGY 2010;51:165-173.
2. Finn RS. Drug therapy: sorafenib. HEPATOLOGY 2010;51:1843-1849.
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
4. Páez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
5. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.